Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.
Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.
复制标题
DOI：
10.1155/2011/574695
复制
发表时间：
2011
影响因子：
1.1
通讯作者：
Svane IM
中科院分区：
文献类型：
--
作者：
Junker N;Thor Straten P;Andersen MH;Svane IM
将自体肿瘤浸润淋巴细胞（TIL）过继转移至晚期恶性黑色素瘤患者的临床试验已显示出显著结果，在50%的治疗患者中具有客观临床应答。为了启动黑色素瘤的临床试验，我们已经建立了一种方法，在8周内分两步将TIL扩增至临床相关量。扩增的TIL的进一步表征揭示了具有效应记忆样表型的T细胞的寡克隆组成。当自体肿瘤可用时，TIL在所有测试的患者中显示出特异性活性。TIL培养物含有对肿瘤细胞的特异性以及在扩增过程中源自肿瘤相关抗原（TAA）的肽。
Clinical trials of adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) to patients with advanced malignant melanoma have shown remarkable results with objective clinical responses in 50% of the treated patients. In order to initiate a clinical trial in melanoma, we have established a method for expanding TILs to clinical relevant quantities in two steps with in 8 weeks. Further characterization of expanded TILs revealed an oligoclonal composition of T-cells with an effector memory like phenotype. When autologous tumor was available, TILs showed specific activity in all patients tested. TIL cultures contained specificity towards tumor cells as well as peptides derived from tumor-associated antigens (TAAs) during expansion procedures.